Terry Rosen, Arcus CEO

Ar­cus de­clares cryp­tic in­ter­im win for close­ly watched an­ti-TIG­IT drug, but you'll have to wait for the da­ta

Big Phar­ma is rac­ing to carve out an ear­ly lead in TIG­IT, a po­ten­tial third im­mune check­point that could of­fer bil­lions in sales. Roche has led the way there, but small biotech Ar­cus is ad­vanc­ing its own can­di­date along­side some big-name part­ners of their own — and af­ter a mid-stage check-in, the com­pa­ny is go­ing pos­i­tive with very lit­tle on hand to show.

In a cryp­tic up­date, Ar­cus said its an­ti-TIG­IT drug dom­vanal­imab showed “en­cour­ag­ing clin­i­cal ac­tiv­i­ty” in a Phase II open-la­bel study test­ing the drug along­side an in­ves­ti­ga­tion­al PD-1 ther­a­py, and in a triplet ther­a­py in­clud­ing those two drugs and dual adeno­sine A2a/A2b re­cep­tor an­tag­o­nist etru­madenant, in metasta­t­ic non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.